Have a feature idea you'd love to see implemented?
Let us know!
CORT Corcept Therapeutics Inc
Price (delayed)
$55.92
Market cap
$5.86B
P/E Ratio
41.12
Dividend/share
N/A
EPS
$1.36
Enterprise value
$5.73B
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®
Highlights
The EPS has surged by 55% year-on-year and by 11% since the previous quarter
CORT's net income has soared by 55% YoY and by 12% QoQ
The quick ratio is down by 33% since the previous quarter but it is up by 9% year-on-year
The P/E is 74% more than the 5-year quarterly average of 23.7 and 44% more than the last 4 quarters average of 28.6
Corcept Therapeutics's debt has increased by 20% QoQ
Key stats
What are the main financial stats of CORT
Market
Valuations
Earnings
Shares outstanding
104.78M
Market cap
$5.86B
Enterprise value
$5.73B
Price to earnings (P/E)
41.12
Price to book (P/B)
9.15
Price to sales (P/S)
9.2
EV/EBIT
40.34
EV/EBITDA
39.92
EV/Sales
9.11
Revenue
$628.56M
EBIT
$142.01M
EBITDA
$143.51M
Free cash flow
$142.6M
Per share
Balance sheet
Liquidity
EPS
$1.36
Free cash flow per share
$1.38
Book value per share
$6.11
Revenue per share
$6.08
TBVPS
$7.59
Total assets
$784.26M
Total liabilities
$145.42M
Debt
$6.79M
Equity
$638.84M
Working capital
$340.76M
Debt to equity
0.01
Current ratio
3.7
Quick ratio
3.49
Net debt/EBITDA
-0.91
Margins
Efficiency
Dividend
EBITDA margin
22.8%
Gross margin
98.4%
Net margin
22.3%
Operating margin
22.8%
Return on assets
20.2%
Return on equity
24.5%
Return on invested capital
31.4%
Return on capital employed
21.6%
Return on sales
22.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CORT stock price
How has the Corcept Therapeutics stock price performed over time
Intraday
-0.3%
1 week
2.06%
1 month
13.87%
1 year
119.98%
YTD
72.17%
QTD
20.83%
Financial performance
How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$628.56M
Gross profit
$618.75M
Operating income
$143.36M
Net income
$140.47M
Gross margin
98.4%
Net margin
22.3%
CORT's net income has soared by 55% YoY and by 12% QoQ
Corcept Therapeutics's operating income has increased by 46% YoY and by 12% from the previous quarter
The revenue rose by 40% year-on-year and by 10% since the previous quarter
The gross profit is up by 39% year-on-year and by 10% since the previous quarter
Growth
What is Corcept Therapeutics's growth rate over time
Valuation
What is Corcept Therapeutics stock price valuation
P/E
41.12
P/B
9.15
P/S
9.2
EV/EBIT
40.34
EV/EBITDA
39.92
EV/Sales
9.11
The P/E is 74% more than the 5-year quarterly average of 23.7 and 44% more than the last 4 quarters average of 28.6
The EPS has surged by 55% year-on-year and by 11% since the previous quarter
The stock's price to book (P/B) is 76% more than its 5-year quarterly average of 5.2 and 48% more than its last 4 quarters average of 6.2
The company's equity rose by 38% YoY and by 7% QoQ
CORT's P/S is 48% above its 5-year quarterly average of 6.2 and 44% above its last 4 quarters average of 6.4
The revenue rose by 40% year-on-year and by 10% since the previous quarter
Efficiency
How efficient is Corcept Therapeutics business performance
The return on equity is up by 29% year-on-year and by 3.4% since the previous quarter
CORT's return on assets is up by 29% year-on-year and by 4.7% since the previous quarter
CORT's ROIC is up by 5% year-on-year
The return on sales has grown by 4.1% year-on-year
Dividends
What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CORT.
Financial health
How did Corcept Therapeutics financials performed over time
The company's current ratio fell by 34% QoQ but it rose by 4.5% YoY
The quick ratio is down by 33% since the previous quarter but it is up by 9% year-on-year
Corcept Therapeutics's debt is 99% lower than its equity
The company's equity rose by 38% YoY and by 7% QoQ
Corcept Therapeutics's debt has increased by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.